Potential Roles of Hsa_Circ_000839 and Hsa_Circ_0005986 in Breast Cancer Publisher Pubmed



Firoozi Z¹ ; Mohammadisoleimani E² ; Shahi A^{3, 4} ; Mansoori H¹ ; Naghizadeh MM⁴ ; Bastami M⁴ ; Narimansalehfam Z⁵ ; Daraei A⁶ ; Raoofat A⁷ ; Mansoori Y^{1, 4} Show Affiliations
Source: Journal of Clinical Laboratory Analysis Published:2022

Abstract

Background: Breast cancer (BC) is one of the leading causes of death among women around the world. Circular RNAs (circRNAs) are a newly discovered group of non-coding RNAs that their roles are being investigated in BC and other cancer types. In this study, we evaluated the association of hsa_circ_0005986 and hsa_circ_000839 in tumor and adjacent normal tissues of BC patients with their clinicopathological characteristics. Materials and methods: Total RNA was extracted from tumors and adjacent non-tumor tissues by the Trizol isolation reagent, and cDNA was synthesized using First Strand cDNA Synthesis Kit (Thermo Scientific). The expression level of hsa_circ_0005986 and hsa_circ_000839 was quantified using RT-qPCR. Online in silico tools were used for identifying potentially important competing endogenous RNA (ceRNA) networks of these two circRNAs. Results: The expression level of hsa_circ_0005986 and hsa_circ_000839 was lower in the tumor as compared to adjacent tissues. The expression level of hsa_circ_0005986 in the patients who had used hair dye in the last 5 years was significantly lower. Moreover, a statistically significant negative correlation between body mass index (BMI) and hsa_circ_000839 expression was observed. In silico analysis of the ceRNA network of these circRNAs revealed mRNAs and miRNAs with crucial roles in BC. Conclusion: Downregulation of hsa_circ_000839 and hsa_circ_0005986 in BC tumors suggests a tumor-suppressive role for these circRNAs in BC, meriting the need for more experimentations to delineate the exact mechanism of their involvement in BC pathogenesis. © 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.